{"id":"zoledronic-acid-i-v-5-years","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Renal impairment"},{"rate":"10-20%","effect":"Hypocalcemia"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Fever"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Bone pain"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Muscle pain"}]},"_chembl":{"chemblId":"CHEMBL4303669","moleculeType":"Small molecule","molecularWeight":"290.11"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bisphosphonates like zoledronic acid bind to hydroxyapatite in bone, inhibiting osteoclast-mediated bone resorption. This leads to a decrease in bone turnover and an increase in bone density.","oneSentence":"Zoledronic acid i.v. inhibits bone resorption by acting as a bisphosphonate.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:25.436Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of hypercalcemia of malignancy, treatment of bone metastases in patients with hormone-refractory prostate cancer, treatment of multiple myeloma and bone metastases in patients with breast cancer, treatment of osteoporosis in postmenopausal women"},{"name":"Prevention of skeletal fractures in patients with multiple myeloma and bone metastases from solid tumors"}]},"trialDetails":[{"nctId":"NCT01197300","phase":"PHASE3","title":"1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-10-25","conditions":"Osteoporosis","enrollment":25},{"nctId":"NCT00439647","phase":"PHASE3","title":"Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Male Osteoporosis","enrollment":1199},{"nctId":"NCT00132808","phase":"PHASE3","title":"Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-07","conditions":"Osteopenia","enrollment":581},{"nctId":"NCT02808988","phase":"PHASE4","title":"Changes of GCF Levels of RANKL and Osteoprotegerin in Postmenopausal Osteoporosis","status":"COMPLETED","sponsor":"Ondokuz Mayıs University","startDate":"2013-10","conditions":"Chronic Periodontitis","enrollment":47},{"nctId":"NCT02181101","phase":"PHASE3","title":"Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial","status":"COMPLETED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2005-09","conditions":"Breast Neoplasms","enrollment":3754},{"nctId":"NCT01341262","phase":"PHASE2","title":"THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM)","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2002-03","conditions":"Multiple Myeloma","enrollment":378},{"nctId":"NCT00439244","phase":"PHASE3","title":"Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-12","conditions":"Osteoporosis","enrollment":412}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Zoledronic acid i.v. 5 years","genericName":"Zoledronic acid i.v. 5 years","companyName":"Ludwig-Maximilians - University of Munich","companyId":"ludwig-maximilians-university-of-munich","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zoledronic acid i.v. inhibits bone resorption by acting as a bisphosphonate. Used for Treatment of hypercalcemia of malignancy, treatment of bone metastases in patients with hormone-refractory prostate cancer, treatment of multiple myeloma and bone metastases in patients with breast cancer, treatment of osteoporosis in postmenopausal women, Prevention of skeletal fractures in patients with multiple myeloma and bone metastases from solid tumors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}